

**NRXN3 Antibody (C-term)**  
**Affinity Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP18845b**

**Specification**

---

**NRXN3 Antibody (C-term) - Product Information**

Application	WB,E
Primary Accession	<a href="#">Q9HDB5</a>
Other Accession	<a href="#">Q8C985</a> , <a href="#">D0PRN4</a> , <a href="#">Q07310</a> , <a href="#">Q6P9K9</a> , <a href="#">Q9Y4C0</a> , <a href="#">D0PRN3</a> , <a href="#">NP_620426.2</a>
Reactivity	Human
Predicted	Chicken, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	69305
Antigen Region	436-462

**NRXN3 Antibody (C-term) - Additional Information**

**Gene ID** 9369

**Other Names**

Neurexin-3-beta, Neurexin III-beta, Neurexin-3-beta, soluble form, Neurexin-3-beta, C-terminal fragment, NRXN3-CTF, NRXN3, KIAA0743

**Target/Specificity**

This NRXN3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 436-462 amino acids from the C-terminal region of human NRXN3.

**Dilution**

WB~~1:1000

**Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

**Storage**

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

NRXN3 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

**NRXN3 Antibody (C-term) - Protein Information**

**Name** NRXN3 ([HGNC:8010](#))

### Synonyms KIAA0743

**Function** Neuronal cell surface protein that may be involved in cell recognition and cell adhesion. May mediate intracellular signaling (By similarity). Functions as part of a trans-synaptic complex by binding to cerebellins and postsynaptic GRID1. This interaction helps regulate the activity of NMDA and AMPA receptors at hippocampal synapses without affecting synapse formation. NRXN3B-CBLN2-GRID1 complex transduce presynaptic signals into postsynaptic AMPAR response (By similarity).

### Cellular Location

Presynaptic cell membrane {ECO:0000250|UniProtKB:Q8C985}; Single-pass type I membrane protein

### Tissue Location


Expressed in the blood vessel walls (at protein level).

### NRXN3 Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### NRXN3 Antibody (C-term) - Images



NRXN3 Antibody (C-term)(Cat. #AP18845b) western blot analysis in CEM cell line lysates (35ug/lane). This demonstrates the NRXN3 antibody detected the NRXN3 protein (arrow).

### NRXN3 Antibody (C-term) - Background

Neurexins are a family of proteins that function in the vertebrate nervous system as cell adhesion molecules and receptors. They are encoded by several unlinked genes of which two, NRXN1 and

NRXN3, are among the largest known human genes. Three of the genes (NRXN1-3) utilize two alternate promoters and include numerous alternatively spliced exons to generate thousands of distinct mRNA transcripts and protein isoforms. The majority of transcripts are produced from the upstream promoter and encode alpha-neurexin isoforms; a much smaller number of transcripts are produced from the downstream promoter and encode beta-neurexin isoforms. The alpha-neurexins contain epidermal growth factor-like (EGF-like) sequences and laminin G domains, and have been shown to interact with neurexophilins. The beta-neurexins lack EGF-like sequences and contain fewer laminin G domains than alpha-neurexins. [provided by RefSeq].

### **NRXN3 Antibody (C-term) - References**

Saus, E., et al. J Psychiatr Res 44(14):971-978(2010)  
Hotta, K., et al. J. Hum. Genet. (2010) In press :  
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :  
Cirulli, E.T., et al. Eur. J. Hum. Genet. 18(7):815-820(2010)  
Novak, G., et al. World J. Biol. Psychiatry 10 (4 PT 3), 929-935 (2009) :